[1] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版).中华肝脏病杂志,2022,30(12):1309-1331.
[2] 朱世殊, 董漪, 徐志强, 等. 1～7 岁慢性乙型肝炎HBeAg 阳性儿童经抗病毒治疗HBsAg 清除率的回顾性研究. 中华肝脏病杂志, 2016, 24(10):738-743.
[3] 李静,樊佩瑶,洪卫国,等.儿童慢性乙型肝炎免疫耐受期的特点和抗病毒治疗研究进展.中华肝脏病杂志, 2022, 30(11):1259-1265.
[4] 尤红,孙亚朦,张梦阳,等.《慢性乙型肝炎防治指南(2022年版)》更新要点解读.中华肝脏病杂志,2023,31(04):385-388.
[5] 谢艳迪,封波,饶慧瑛.《慢性乙型肝炎防治指南(2022年版)》解读.临床肝胆病杂志,2023, 39(07): 1553-1559.
[6] 常思敏.参考文献引用中的学术不端行为分析.出版科学,2007(05):23-25.
[7] Li J,Fan P,Xu Z,et al.Functional Cure of Chronic Hepatitis B with Antiviral Treatment in Children having High-level Viremia and Normal or Mildly Elevated Serum Aminotransferase. J Clin Transl Hepatol,2023.
[8] 朱世殊,董漪,张鸿飞,等. 慢性乙型肝炎儿童免疫耐受期随机对照干扰素序贯联合拉米夫定抗病毒治疗的疗效影响因素研究.中华肝脏病杂志,2019,27(08):604-609.
[9] 吕亚平.学术论文参考文献不良引用行为分析及防范措施浅议.图书馆工作与研究,2012(11):53-56.
[10] 彭婧,姚云清.隐匿性乙型肝炎病毒感染者的自然史与免疫学研究现状.中华内科杂志,2023,62(01): 103-106.
[11] EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol,2017,67(2):370–398.
[12] Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol.2008,49(4):652-657.
[13] Peng J,Yao X,Yuan C, et al.The investigation of hepatitis B vaccine immune responses in occult hepatitis B virus?infected patients. Front Immunol,2022,13:903685.
[14] Xia R,Peng J,He J,et al.The serious challenge of occult hepatitis B virus infection-related hepatocellular carcinoma in China. Front Microbiol,2022,13:840825.
[15] 庄辉.全球和我国HBV感染免疫耐受期患者人数估计更正说明.临床肝胆病杂志,2021,37(04):785-786.
[16] Korean Association for the Study of the Liver(KASL). Erratum to 'KASL clinical practice guidelines for management of chronic hepatitis B'[Clin Mol Hepatol 2022;28:276-331]. Clin Mol Hepatol,2022,28(4):940. |
